Tag Archives: PHA

PR Newswire

111 to Announce Second Quarter 2020 Unaudited Financial Results on August 20, 2020

Leave a comment

SHANGHAI, July 31, 2020 — 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a Company dedicated to digitally connecting patients with drugs and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2020, before the U.S. market opens on Thursday, August 20, 2020.

111’s management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 20, 2020 (7:30 PM Beijing Time on the same day).

Details for the conference call are as follows:

Event Title:                       

111, Inc. Second Quarter 2020 Earnings Conference Call

Registration Link:            

http://apac.directeventreg.com/registration/event/7482148

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.

Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.

A telephone replay of the call will be available after the conclusion of the conference call until August 28, 2020, 09:59 P.M. ET on:

United States:                    

+1-855-452-5696

International:                      

+61-2-8199-0299

Conference ID:                   

7482148

A live and archived webcast of the conference call will be available on the Investor Relations section of 111’s website at http://ir.111.com.cn/.

About 111, Inc.

111, Inc. (NASDAQ: YI) ("111" or the "Company") is a Company dedicated to digitally connecting patients with drugs and healthcare services in China. The Company provides hundreds of millions of consumers with better access to pharmaceutical products and medical services directly through its online retail pharmacy and indirectly through its offline pharmacy network. 111 also offers online medical services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation and electronic prescription services. In addition to providing direct services to consumers through its online retail pharmacy, 111 also enables offline pharmacies to better serve their customers.  The Company’s online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. The Company’s New Retail platform, by integrating the front and back ends of the pharmaceutical supply chain, has formed a smart supply chain, which transforms the flow of pharmaceutical products to pharmacies and modernizes how they serve their customers.

For more information on 111, please visit: http://ir.111.com.cn/.

For more information, please contact:

111, Inc.
Investor Relations
Email: ir@111.com.cn

111, Inc.
Media Relations 
Email: press@111.com.cn 
Phone: +86-021-2053 6666 (China)

GCM Strategic Communications
IR Counsel
Email: 111.ir@gcm.international

Related Links :

http://www.yiyaowang.com

PR Newswire

Carromex Unveils Pharma Leads, a Groundbreaking Cloud-based Platform for Rapid Drug Analysis and Discovery

Leave a comment

Mathematical Breakthrough by Australia-based Research Team Leads to a Shortening of Drug Discovery Times and Efficacy Analysis

SYDNEY and MELBOURNE, Australia, July 10, 2020 — Carromex, a mathematical research-based innovation company based in Australia, unveiled a new cloud-based pharmaceutical software platform called Pharma Leads https://carromex.com/products/pharma-leads/, that is set to significantly contribute to the advancement of the healthcare and pharmaceutical industry today. 

The platform provides pharmaceutical companies and researchers with two unique benefits: 

  • First, users can discover potential treatments by merely inputting the genetic sequence of the disease, dramatically reducing the time and costs associated with searching for new treatments.
  • Second, researchers and pharmaceutical companies can rapidly assess the safety and efficacy of the therapy by analyzing its genetic makeup to test if the combination will be harmful to the body.

The discovery was first made by Dr Burzin Bhavnagri while in pursuit of his Ph. D. at the University of Adelaide and is now available publicly for the first time. 

"Representational Consistency is an exciting and entirely new field of mathematics. In my thesis on the development of "Computer Vision using Shape Spaces" and my desire to apply the theory to a real-world example of cancer drug treatment, I discovered a formula which led to the creation of Pharma Leads", said Dr. Burzin.

From the Search for a Cure for Cancer to a Healthcare Breakthrough

In 2012, using his discovery of Representational Consistency, Dr Burzin began to research the 30 known definite carcinogens listed by the International Agency of Cancer Research (IARC), where he discovered a link between representational inconsistency and carcinogens, prompting the search for a cancer treatment using the theory. 

Dr Burzin then discovered that the same process could be used to dramatically reduce the research time and costs associated with drug development and discovery, leading to the creation of the Pharma Leads platform. 

Using Computer Vision to Revolutionize the Pharmaceutical Industry

Pharma Leads by Carromex is an interactive online program that works in silico without the need for a database which can systematically analyze a chemical structure or gene sequence. 

The revolutionary platform allows users to access a list of amino acids for a protein sequence or a list of nucleic acids for a gene sequence. The user can also enter the name of the medicines or their chemical structure to analyze a drugs safety and efficacy. 

"Users can choose from searching for a treatment or analyze how a chemical compound may interact with RNA or DNA, for instance, Acetaminophen," Dr Burzin explained further. 

Pharma Leads by Carromex is currently available on Google Cloud for users in the United States. 

For more information, please visit https://carromex.com/products/pharma-leads/ 

About Carromex and the Invention of Pharma leads 

Carromex was founded in the 1980s by the late Dr Nina Bhavnagri and her son Dr Burzin Bhavnagri. For the last eight years, the company has been focusing on mathematical research and program design. 

Related Links :

http://www.carromex.com

PR Newswire

Clarivate Introduces Next Generation Insights Platform with Cortellis Generics Intelligence

Leave a comment

Enhanced Newport platform allows for comprehensive and accurate analysis of market, API and patent data from a single application

LONDON, July 1, 2020 — Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of Cortellis Generics Intelligence™ to enable generics companies and Active Pharmaceutical Ingredient (API) manufacturers to make timely and more informed data-driven decisions as they seek to drive business growth, identify new markets, products and partners, defend market share and more. The modern, intuitive platform enables sourcing, business development, portfolio and intellectual property teams within an organization to make data-driven decisions – all from a single application.


Cortellis Generics Intelligence powered by Clarivate Research Intelligence Cloud replaces and enhances the well-known Newport platform from Clarivate. It includes new intuitive search capabilities together with expertly curated data on market performance, patents and litigation, and manufacturers to assist finished dose manufacturers, API manufacturers, and pharmaceutical marketers in their pursuit to successfully launch generic drugs and maintain a steady supply chain.

This comprehensive database collates crucial market, API, and patent data, including sales and consumption data, product launches, company information, Paragraph IV patent challenges, API suppliers’ regulatory filings and more. With seamless connectivity to the broader Cortellis suite of life science intelligence solutions, researchers will have comprehensive access to high-quality drug development, clinical trial, deal-making and regulatory intelligence.

Keith Collier, Senior Vice President of Product Management, Clarivate said: "The generics industry is extremely competitive with a high degree of uncertainty and complexity in bringing a drug to market or identifying APIs with the most market potential. All teams within a company are involved in making decisions that will ultimately impact their company’s achievements and risk making the wrong decision based on partial data. Cortellis Generics Intelligence is the most comprehensive source of market performance, patent and manufacturing data, allowing generics and API companies to easily connect the dots between key areas of intelligence, so they can validate their strategy with the assurance they haven’t missed any critical considerations. Ultimately, this will allow them to quickly shift from market research and assessment to actually implementing their strategic priorities."

According to The Centre for Medicines Research (CMR) International, over the next seven years, 114 products are predicted to lose exclusivity and become generic within the U.S. ― 8% of which are currently blockbuster products1. This number is scheduled to increase each year from now until 2022. Due to high demand within the blockbuster space, selecting the right drug for investment requires precision. The number of Abbreviated New Drug Application (ANDA) final approvals granted by the FDA to Indian- and U.S.- headquartered companies saw a marked decrease in 2018, further supporting the need to identify the right drugs for investment to ultimately secure ANDA approval2. In addition, the number of products exposed to Paragraph IV challenges in the U.S. has continued to rise over the past four years3, indicating that more companies are looking to launch generic drugs around the world, which heightens competition. Similar dynamics are in play in other major markets around the world. These points reinforce the need for greater accuracy early in the generics lifecycle to develop a validated launch strategy and identify less promising portfolio candidates earlier – enabling the most effective use of time and resources.

Cortellis Generics Intelligence is comprised of data spanning more than 64,000 small molecules and biologics, 72,000 manufacturers and marketers, 1.1 million worldwide patents, 62,000 regulatory documents across 25+ countries, and more. Additional analytics and functionality will continue to be added throughout 2020 and 2021 to further aid with generics companies’ strategies and decision-making. The data will continue to be updated daily and expand into additional analytics to support market share analysis, the impact of litigation on generic launches and competitive assessments.

To learn more about Cortellis Generics Intelligence, visit http://www.clarivate.com/genericsintelligence.

About Clarivate

Clarivate™ is a global leader in providing trusted information and insights to accelerate the pace of innovation. We offer subscription and technology-based solutions coupled with deep domain expertise that cover the entire lifecycle of innovation – from foundational research and ideas to protection and commercialization. Today, we’re setting a trail-blazing course to help customers turn bold ideas into life-changing inventions. Our portfolio consists of some of the world’s most trusted information brands, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. For more information please visit www.Clarivate.com.

Forward-Looking Statements
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate. Forward-looking statements provide Clarivate’s current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate’s control that may cause actual results to differ materially. Clarivate undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.

1 Clarivate Analytics (2019), 2019 CMR International Pharmaceutical R&D Factbook, https://discover.clarivate.com/2019CMRFactbook 
2 Clarivate Analytics (2019), 2019 CMR International Pharmaceutical R&D Factbook, https://discover.clarivate.com/2019CMRFactbook
3 Clarivate Analytics (2019), 2019 CMR International Pharmaceutical R&D Factbook, https://discover.clarivate.com/2019CMRFactbook 

Logo – https://techent.tv/wp-content/uploads/2020/07/clarivate-introduces-next-generation-insights-platform-with-cortellis-generics-intelligence.jpg

Related Links :

http://www.Clarivate.com

PR Newswire

Berkeley Lights Launches Two New Capabilities in the Opto Cell Therapy Development 1.0 Workflow to Accelerate the Creation Of Effective Cancer Immunotherapies

Leave a comment

The new multiplex cytokine and cytotoxicity assays as a part of the Opto Cell Therapy Development 1.0 workflow will help users of the Berkeley Lights’ platform develop cancer immunotherapies faster

EMERYVILLE, Calif., April 28, 2020 /PRNewswire/ — Today, Berkeley Lights, Inc., a leader in Digital Cell Biology, launched new capabilities to empower the Opto Cell Therapy Development 1.0 workflow. The workflow consists of a collection of software capabilities, reagents, and protocols to be run on the Beacon® and LightningTM systems. With the new capabilities researchers can now perform multiple functional assays on thousands of individual T cells in just days, allowing them to recover live cells for downstream genomic analysis. This ultimately enables Berkeley Lights’ customers to link T cell phenotype and function to genotype on individual cells, consolidating the T cell functional analytic process into one innovative platform.

T cell-based therapies have shown great promise for cancer treatment, but developing these therapies is challenging because the process of killing cancerous tumors by T cells relies on studying and screening multiple cell-to-cell interactions—a time-consuming and complex procedure. Current techniques to assess T cell function don’t allow scientists to collect all of the required data from the same cell. The new multiplex cytokine assay and the cytotoxicity assay, along with the recently launched TCRseq Well Plate Kit allow scientists to define and test the function of individual T cells. These applications enable simultaneous functional interrogation of thousands of individual T cells as they interact with antigen-presenting cells or tumors. Live, individual clones can be recovered for downstream expansion or genomic analysis. The Opto Cell Therapy Development 1.0 workflow enables CAR-T cell phenotypic and functional screening, and the discovery of T cell receptors (TCRs) associated with specific T cell behaviors.

“With the Opto Cell Therapy Development 1.0 workflow, users of Berkeley Lights’ platform can now tailor the development of cell therapies that mediate the rapid destruction of multiple tumor cells to the few T cells that really do all the work,” said John Proctor, Ph.D., Senior Vice President of Marketing at Berkeley Lights. “The cytotoxicity assay visualizes killing activity from single T cells, such as multiplexed and serial killing, followed by live cell recovery for genomic analysis. This new assay avoids common problems associated with traditional killing assays, which measure average target cell lysis at fixed time points, obscuring kinetic details and ignoring the heterogeneity present in T cell subsets.”

Berkeley Lights will continue to release more cell therapy related capabilities to the Berkeley Lights platform in the coming months. Email info@berkeleylights.com for more info.

About Berkeley Lights
 Here at Berkeley Lights, we think cells are awesome! Cells are capable of manufacturing cures for diseases, fibers for clothing, energy in the form of biofuels, and food proteins for nutrition. So the question is, if nature is capable of manufacturing the products we need in a scalable way, why aren’t we doing more of this? Well, the answer is that with the solutions available today, it is hard. It takes a long time to find the right cell for a specific job, costs lots of money, and if you have picked a suboptimal cell line, has a very low process yield. The Berkeley Lights Platform delivers and links deep phenotypic, functional, and genotypic information at the single cell level. This is a new way to capture and interpret the qualitative language of biology and translate it into single cell specific digital information, which we call Digital Cell Biology. Using our platform, customers have the complete solution to find the best cells by functionally screening and recovering individual cells for antibody discovery, cell line development, cell therapy development, and synthetic biology. Using our systems and solutions, scientists can find the best cells, the first time they look. For more information, visit www.berkeleylights.com.

Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are for research use only. Not for use in diagnostic procedures.

Logo – https://techent.tv/wp-content/uploads/2020/04/berkeley-lights-launches-two-new-capabilities-in-the-opto-cell-therapy-development-1-0-workflow-to-accelerate-the-creation-of-effective-cancer-immunotherapies.jpg  

Source: Berkeley Lights, Inc.